Basic Ranexa Information

• INN (International Nonproprietary Name): Ranolazine.
• Brand Names Available In United Kingdom: Ranexa and generics marketed by Accord.
• ATC Code: C01EB18 (Other Antianginal Agents).
• Forms & Dosages: Extended‑release tablets in 375 mg, 500 mg and 750 mg strengths; 1000 mg tablets are seldom available outside North America and Australia.
• Manufacturers In United Kingdom: Menarini and generic distributors such as Accord.
• Registration Status In United Kingdom: Prescription‑only medicine licensed for chronic stable angina in adults under MHRA/EMA regulatory frameworks.
• OTC / Rx Classification: Prescription‑only (Rx).

Major 2022–2025 Studies

Worried this is just old data and not relevant to modern care?

Recent randomised and real‑world cohort analyses between 2022 and 2025 reaffirmed ranolazine’s role as an adjunctive antianginal for chronic stable angina.

These studies evaluated ranolazine on top of background therapy such as β‑blockers, calcium channel blockers and nitrates.

Outcomes included improved exercise tolerance and fewer weekly angina episodes in patients with refractory symptoms.

Effect sizes reported were modest but clinically meaningful for patients still symptomatic after standard therapy.

Investigations that explored atrial arrhythmia endpoints remained exploratory and did not provide a licence extension.

Trials emphasised symptomatic benefit rather than mortality or hospitalisation reductions.

Where exercise tolerance was measured, treadmill duration increased compared with placebo in several cohorts.

Real‑world datasets supported efficacy findings from randomised trials and highlighted tolerability in routine practice.

Clinicians using ranolazine alongside established agents reported additive symptom control without further heart‑rate suppression.

Main Outcomes

Do patients actually feel better on ranolazine?

Consistent primary outcomes across trials were fewer angina episodes and longer exercise duration on treadmill testing.

Some patient subsets showed improvement in Canadian Cardiovascular Society angina class.

Benefits were observed independently of heart‑rate reduction, matching ranolazine’s late‑INa mechanism.

Symptom relief tended to be most apparent in refractory patients who could not escalate standard agents.

Where reported, changes in quality‑of‑life scores were modest but reproducible across datasets.

Safety Observations

Is ranolazine safe for routine use?

Safety findings in contemporary studies mirrored established post‑marketing data.

Common adverse events were constipation, nausea and dizziness.

QT interval prolongation occurred in a dose‑related manner but was infrequent at typical UK doses.

Drug‑interaction risk with CYP3A modulators remained the primary safety concern and required dose adjustments or avoidance.

Layman’s Explanation

Wondering how ranolazine actually eases chest pain without making the pulse slow?

Ranolazine helps the heart use oxygen more efficiently during stress, which reduces pain from ischaemia.

It limits abnormal sodium entry into heart cells during stress, which prevents calcium overload inside the muscle.

The net effect is lower diastolic tension and reduced oxygen demand without large drops in heart rate or blood pressure.

That makes it useful for people who cannot tolerate further heart‑rate lowering from β‑blockers.

Scientific Breakdown

Want the technical mechanism in plain scientific terms?

The primary molecular target is inhibition of the late inward sodium current (late‑INa) in cardiomyocytes.

By reducing late‑INa, ranolazine lowers intracellular sodium and thereby limits calcium overload through the sodium‑calcium exchanger.

Secondary effects include modest inhibition of the rapid delayed rectifier potassium current (IKr) at higher concentrations, which explains dose‑dependent QT changes.

Pharmacokinetics

How is ranolazine given and processed by the body?

It is supplied as an extended‑release oral tablet to provide steady plasma concentrations over 12 or 24 hours depending on formulation.

Common UK tablet strengths are 375 mg, 500 mg and 750 mg as marketed by Menarini and generics such as Accord.

Ranolazine is primarily metabolised by CYP3A and to a lesser extent by CYP2D6.

Renal or hepatic impairment affects clearance and increases exposure, which raises QT risk.

Clinical Implication

Who benefits most from ranolazine in practice?

Because it does not substantially lower heart rate, ranolazine is suited to patients with ischaemia that is independent of tachycardia.

It is also an option when patients cannot tolerate further rate‑lowering therapy or when blood pressure is limiting dose increases of other agents.

United Kingdom Approvals

Is ranolazine licensed for use here?

In the United Kingdom ranolazine (Ranexa and generics such as Accord) is a prescription‑only extended‑release tablet indicated for chronic stable angina as adjunctive therapy when standard antianginal therapy is insufficient.

MHRA and EMA approvals are aligned with international labelling and cover adult use only.

Severe hepatic impairment is a contraindication and clinicians should consider QT risk when prescribing.

Notable Off‑Label Trends

Could ranolazine be useful for conditions beyond angina?

Investigational and off‑label uses reported in the literature include atrial fibrillation prevention and symptomatic diastolic dysfunction.

Evidence for these uses remains preliminary and does not support licensing for those indications.

UK practice reserves ranolazine for selective use in refractory angina or where rate‑lowering is undesirable.

General Dosing

What dose should a typical adult start on?

Standard adult initiation is 500 mg extended‑release twice daily.

Titration may proceed to 1000 mg twice daily (maximum 2000 mg/day) subject to response and tolerability.

In the UK the 1000 mg tablet is uncommon, so titration commonly uses available 375 mg, 500 mg and 750 mg strengths.

Condition‑Specific Dosing

How is ranolazine used for chronic stable angina specifically?

For chronic stable angina start at 500 mg twice daily and reassess after 2–4 weeks.

Up‑titration is an option if symptoms persist and side effects are acceptable.

Hepatic/Renal Factors

Should dosing change with organ impairment?

Ranolazine is contraindicated in severe hepatic impairment and dose reduction or avoidance is advised in moderate disease.

Use caution in severe renal impairment where accumulation and QT risk increase, and consider alternatives.

Elderly

Is age a reason to lower the dose immediately?

No routine age‑based dose change is mandated, but monitor patients over 75 years for QT prolongation and dizziness.

Greater clinical vigilance is advisable rather than automatic dose reduction.

Contraindications

Who must never take ranolazine?

Absolute contraindications include hypersensitivity to ranolazine, severe hepatic impairment and known congenital or acquired long QT syndrome.

Concurrent use with strong CYP3A inhibitors such as ketoconazole or clarithromycin is also contraindicated.

Severe renal impairment is advised against in labelling and should be avoided in practice.

Adverse Effects

What side effects should patients expect?

Common mild events are constipation, nausea, headache and dizziness.

Less common but clinically notable effects include palpitations, syncope and increased blood pressure.

QT prolongation is dose‑dependent and becomes important when interacting drugs or organ impairment are present.

Monitoring Strategy

What monitoring is recommended in UK practice?

Obtain a baseline ECG for patients with QT risk factors and repeat if symptoms such as syncope or palpitations occur, or if the dose is escalated.

Review all concomitant medicines for CYP3A and CYP2D6 interactions before initiation.

Monitor hepatic and renal function where indicated and follow local cardiology formulary guidance.

Food Interactions

Can patients eat or drink normally while taking ranolazine?

There are no major food restrictions in standard labels, but taking the extended‑release tablet consistently with meals improves tolerability for some patients.

Avoid grapefruit juice because it inhibits CYP3A and can raise ranolazine exposure and QT risk.

Drug Combinations To Avoid

Which medicines must be avoided with ranolazine?

Strong CYP3A inhibitors such as ketoconazole, clarithromycin and ritonavir are contraindicated.

Strong CYP3A inducers like rifampicin and carbamazepine may reduce ranolazine efficacy.

Caution is required with moderate CYP3A inhibitors and dose reduction or alternative therapy should be considered.

Combining ranolazine with other QT‑prolonging drugs increases arrhythmia risk and should be avoided where possible.

Practical UK Checks

How can pharmacists screen safely at the counter?

UK medication review tools such as the BNF and local clinical decision support systems should flag ranolazine interactions during dispensing.

Provide pharmacy counselling that highlights CYP3A interactions and the need to report syncope or palpitations.

Survey Data

Do patients report feeling better after starting ranolazine?

Patient‑reported outcomes in recent cohorts indicate fewer angina attacks and improved activity tolerance when ranolazine is added to existing therapy.

Quality‑of‑life benefits were modest but consistent in refractory patient groups.

Side effects such as constipation and mild nausea were commonly cited and led to discontinuation in a minority.

Forum Trends

What do UK support groups say about ranolazine?

Patient forums report generally positive functional improvements but occasional comments about supply or availability issues for some strengths.

Many patients value ranolazine when it allows higher exertion without bradycardia or dizziness.

Distribution & Pricing Landscape

Is ranolazine easy to source and affordable in the UK?

Ranexa (Menarini) and generics such as Accord supply extended‑release tablets in 375 mg, 500 mg and 750 mg strengths in the UK market.

It is prescription‑only via MHRA and available through community pharmacies and hospital supply chains.

Generic competition since patent expiry has reduced cost and increased formulary uptake in many areas.

Occasional supply interruptions for specific strengths have been reported internationally, so procurement teams should maintain alternative suppliers.

Reimbursement And Prescribing

Who usually starts ranolazine and who continues it?

Ranolazine is typically initiated by cardiology specialists in secondary care with primary‑care repeat prescribing following local formulary guidance.

Pharmacy counselling should include storage at 20–25°C and interaction warnings at dispensing.

Comparison Table

What are the main alternatives to ranolazine for chronic stable angina?

Alternatives include nitrates such as isosorbide mononitrate for rapid symptom relief but with tolerance risk.

β‑blockers like metoprolol and bisoprolol reduce heart rate and have mortality benefits post‑MI.

Calcium channel blockers such as amlodipine, diltiazem and verapamil provide vasodilation and rate control options.

Other adjunct agents include ivabradine and nicorandil which have different mechanisms.

Pros And Cons

Why choose ranolazine over other options?

Advantages of ranolazine include being non‑nitrate and having minimal effect on heart rate and blood pressure.

It is suitable when rate‑lowering agents are poorly tolerated.

Disadvantages include QT prolongation risk, CYP3A interactions, contraindication in severe hepatic impairment and variable availability of higher strengths in the UK.

Regulatory Status

Is ranolazine still a licensed medicine in 2025?

As of the latest product information, ranolazine (INN: ranolazine) is prescription‑only in the UK and EU and licensed for chronic stable angina in adults.

MHRA and EMA labelling aligns with other regulators and includes contraindications and monitoring requirements.

Primary manufacturers supplying the UK include Menarini and generic distributors such as Accord.

Clinicians should consult the electronic Medicines Compendium for up‑to‑date SPCs and safety communications.

Who Should Be Offered Ranolazine?

Is ranolazine suitable for every angina patient?

Offer ranolazine to adults with chronic stable angina who remain symptomatic despite optimisation of first‑line agents or who cannot tolerate those agents.

Specialist initiation is recommended and primary‑care repeat prescribing should follow local guidance.

What Dose Is Used In The UK?

What practical dosing advice should patients receive?

Start at 500 mg twice daily and consider titration based on symptoms and tolerability.

Remember that 1000 mg tablets are uncommon in the UK and titration often uses 375 mg, 500 mg and 750 mg tablets.

Is ECG Monitoring Required?

Do patients need routine ECGs while taking ranolazine?

Baseline ECG for QT risk factors is prudent and repeat ECGs should be performed if symptoms suggest arrhythmia or when interacting drugs are added.

Can It Be Used With β‑Blockers?

Are there interactions with rate‑lowering drugs?

Yes, ranolazine is commonly used in combination with β‑blockers without additive bradycardia and is often prescribed when additional symptom control is needed.

Is Ranolazine Safe In Liver Disease?

Can patients with liver problems take ranolazine?

Ranolazine is contraindicated in severe hepatic impairment and should be used cautiously or avoided in moderate hepatic dysfunction.

Visual Guide Suggestions

Would a simple visual help explain ranolazine to patients?

Suggested visuals include an infographic of mechanism showing late‑INa inhibition leading to reduced diastolic tension.

A flowchart can outline initiation: specialist assessment → start 500 mg BID → review 2–4 weeks → consider titration.

A table summarising common side effects and management (for example, treat constipation, avoid grapefruit) aids counselling.

An interaction matrix that flags strong CYP3A inhibitors/inducers and QT‑prolonging drugs in red will be practical for prescribers.

Designs should use UK‑centric labels and reference ER tablet strengths of 375/500/750 mg with storage guidance at 20–25°C.

Storage Conditions

How should ranolazine be stored at home?

Store extended‑release tablets at controlled room temperature between 20–25°C and protect from moisture, heat and light.

Keep the tablets in their original blister packs and out of reach of children.

Transport And Stock Handling

What should pharmacies do on receipt of stock?

Avoid extremes of temperature and protect blister packs during transport and storage.

Pharmacies should check batch integrity on receipt and advise patients to avoid storing tablets in bathrooms where humidity is high.

Procurement teams should note occasional strength‑specific shortages and keep alternative suppliers on contract.

Prescribing Checklist

What steps should a prescriber follow before starting ranolazine?

Confirm the indication is chronic stable angina after optimisation of first‑line agents.

Perform baseline assessments such as ECG for QT risk, liver function tests and a medication review for CYP3A interactions.

Start at 500 mg twice daily and document a reassessment plan for possible titration.

Counselling should cover taking the ER tablet whole, consistent dosing with meals, not doubling missed doses and reporting syncope or palpitations promptly.

Advise patients to avoid grapefruit and to inform other clinicians about ranolazine use in perioperative and emergency settings.

Clinical governance should align use with local cardiology formulary pathways and include adverse‑event reporting to the MHRA where relevant.

Ordering And Access

How can patients obtain ranolazine in the UK?

Ranolazine is prescription‑only and is usually provided following specialist initiation and an appropriate prescription.

Our online pharmacy can supply ranexa with a valid prescription, with discreet delivery to the United Kingdom in 5–14 days.

Delivery Across United Kingdom

Alternative Options Summary

Which options should clinicians consider instead of ranolazine?

Consider nitrates for rapid relief and beware tolerance with long‑term use.

Use β‑blockers when heart‑rate lowering is appropriate, particularly after myocardial infarction.

Calcium channel blockers offer vasodilation and varying effects on rate depending on the agent.

Ivabradine or nicorandil may be useful adjuncts for selected patients with contraindications to other drugs.

Closing Practical Notes

What should a patient remember before taking ranolazine?

Take ER tablets exactly as directed and do not crush or chew them.

Maintain regular follow‑up with the initiating cardiology team and report any fainting spells, palpitations or new medications promptly.

Check with pharmacy staff about potential interactions when starting any new drug.

Keep ranolazine in its original packaging and store at controlled room temperature between 20–25°C.

References And Resources

Where to check the latest product and safety information?

Clinicians should consult the electronic Medicines Compendium (eMC) and local formularies for the current summary of product characteristics and any MHRA safety communications.